3.46
+10.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Galectin Therapeutics
From its filings with the US Securities and Exchange Commission
Galectin Therapeutics is based in Norcross, Georgia and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker GALT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $30.8m. At that date it held total assets of $19.5m and shareholders' equity of −$127.9m.
Our lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis and in clinical studies to decrease portal hypertension and prevent its complication: the development of esophageal varices. Belapectin has the potential to treat many diseases due to galectin-3’s involvement in multiple key biological pathways such as fibrosis, immune cell function and immunity, cell differentiation, cell growth, and apoptosis (cell death). The importance of galectin-3 in the fibrotic process is supported by experimental evidence. Animals with the galectin-3 gene “knocked-out” can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene. We are using our galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in MASH patients. We have completed two Phase 1 clinical studies, a Phase 2 clinical study in MASH patients with advanced fibrosis (NASH-FX) and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension (NASH-CX).
Quoted from its 10-K, filed 31 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Sept 2002
- Employees
- 9
- Website
- galectintherapeutics.com ↗
- Head office
- 4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA, 30071
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Richard UihleinIndependent Chairman of the Board$98,000
- Mr. Joel LewisPresident, Chief Executive Officer, Director, since 2017$1.2m
- Mr. Jack CallicuttChief Financial Officer$716,945
- Dr. Khurram JamilChief Medical Officer$945,847
- Dr. Benjamin CarsonDirector$98,000
- Dr. Gilbert AmelioIndependent Director$113,500
- Mr. Kary EldredIndependent Director$105,500
- Mr. Kevin FreemanIndependent Director$114,000
- Dr. Gilbert OmennIndependent Director$108,000
- Dr. Marc RubinIndependent Director, since 2011$101,500
- Ms. Elissa SchwartzIndependent Director$101,500
- Dr. Harold ShlevinIndependent Director, since 2012$98,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 31
- Social
- 55
- Governance
- 9
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Galectin Therapeutics Inc has a strong portfolio of drug candidates with potential therapeutic applications in various diseases.
- The company has established collaborations with renowned academic institutions and research organizations, which enhances its research capabilities.
- Galectin Therapeutics Inc has a dedicated team of experienced scientists and professionals who have expertise in the field of galectin biology.
Weaknesses
- The company is highly dependant on the success of its drug candidates, which are still in various stages of clinical trials. Failure in any of the trials could have a negative impact on the company's financial performance.
- Galectin Therapeutics Inc has a limited number of drug candidates in its pipeline, which may restrict its ability to capture a larger market share.
- The company has relatively limited financial resources, which may hinder its ability to fully develop and commercialize its drug candidates.
Opportunities
- There is a growing demand for innovative therapies targeting various diseases, which presents an opportunity for Galectin Therapeutics Inc to capture a larger market share.
- The company can explore partnerships and collaborations with pharmaceutical companies to increase its research and development capabilities and accelerate the commercialization of its drug candidates.
- The increasing prevalence of certain diseases, such as liver fibrosis and cancer, provides a potential market opportunity for Galectin Therapeutics Inc to address unmet medical needs.
Threats
- The pharmaceutical industry is highly competitive, with many established companies and emerging biotechnology firms, which may pose a challenge for Galectin Therapeutics Inc to differentiate itself and gain market acceptance.
- There is a risk of regulatory hurdles and delays in obtaining approvals for its drug candidates, which could significantly impact their commercialization and revenue generation.
- Market dynamics, including pricing pressures and reimbursement policies, may affect the profitability of Galectin Therapeutics Inc's products.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.